Arcus Biosciences, Inc. (RCUS)

Arcus Biosciences, Inc. is trading at $18.19, down 2.26% on the session. The 50 day average sits at $26.12 and the 200 day at $24.76, which puts the stock in a uptrend. RSI is at 27.5, which reads as oversold, and MACD is bearish crossover. Volume is volume spike.

The nearest support is around $17.43 with resistance near $24.70, so that band frames the current range. Average daily movement is roughly $1.68, or about 9.3% of the share price, which is what any stop placement has to allow for. The overall health score of 30 out of 100 combines a trend score of 30, momentum of 34 and a risk score of 24.

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.